Chugai Pharmaceutical Co., Ltd. (TYO:4519)
Japan
· Delayed Price · Currency is JPY 6,734.00
+368.00 (5.78%)
Jan 31, 2025, 3:30 PM JST
Chugai Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 387,317 | 325,472 | 374,429 | 302,995 | 214,733 | Upgrade
|
| Depreciation & Amortization | 31,665 | 31,740 | 31,434 | 30,868 | 30,376 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1,421 | -21,881 | 641 | 6,342 | 953 | Upgrade
|
| Asset Writedown & Restructuring Costs | 5,798 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 383 | - | - | - | - | Upgrade
|
| Other Operating Activities | 52,701 | -180,718 | -152,074 | -104,102 | -65,247 | Upgrade
|
| Change in Other Net Operating Assets | -28,843 | 255,312 | -10,318 | 43,523 | 24,220 | Upgrade
|
| Operating Cash Flow | 447,600 | 409,925 | 244,112 | 279,626 | 205,035 | Upgrade
|
| Operating Cash Flow Growth | 9.19% | 67.92% | -12.70% | 36.38% | -0.78% | Upgrade
|
| Capital Expenditures | -50,925 | -71,948 | -62,625 | -65,969 | -57,040 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 19,346 | 1,048 | 1,042 | -22 | Upgrade
|
| Sale (Purchase) of Intangibles | -1,685 | 12,850 | -8,614 | -6,897 | -4,349 | Upgrade
|
| Investment in Securities | -177,539 | 979 | -76,083 | -47,236 | -37,001 | Upgrade
|
| Other Investing Activities | 2,784 | 1,483 | 280 | 133 | 100 | Upgrade
|
| Investing Cash Flow | -227,365 | -37,290 | -145,994 | -118,927 | -98,312 | Upgrade
|
| Long-Term Debt Repaid | -8,148 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -8,148 | - | - | - | - | Upgrade
|
| Issuance of Common Stock | 168 | 217 | 241 | 322 | 440 | Upgrade
|
| Repurchase of Common Stock | -10 | -5 | -5 | -8 | -30 | Upgrade
|
| Common Dividends Paid | -133,249 | - | - | - | - | Upgrade
|
| Dividends Paid | -133,249 | -131,594 | -138,220 | -98,644 | -91,442 | Upgrade
|
| Other Financing Activities | 233 | -7,949 | -7,657 | -9,078 | -8,465 | Upgrade
|
| Financing Cash Flow | -141,006 | -139,331 | -145,641 | -107,408 | -99,497 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2,299 | 3,202 | 1,939 | 2,128 | 1,166 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | -1 | - | - | 1 | Upgrade
|
| Net Cash Flow | 81,528 | 236,505 | -45,584 | 55,419 | 8,393 | Upgrade
|
| Free Cash Flow | 396,675 | 337,977 | 181,487 | 213,657 | 147,995 | Upgrade
|
| Free Cash Flow Growth | 17.37% | 86.23% | -15.06% | 44.37% | -3.67% | Upgrade
|
| Free Cash Flow Margin | 33.89% | 30.41% | 14.40% | 21.37% | 18.81% | Upgrade
|
| Free Cash Flow Per Share | 241.05 | 205.39 | 110.30 | 129.86 | 89.96 | Upgrade
|
| Cash Interest Paid | 94 | 81 | 58 | 48 | 34 | Upgrade
|
| Cash Income Tax Paid | 100,477 | 176,074 | 152,082 | 104,074 | 66,785 | Upgrade
|
| Levered Free Cash Flow | 338,076 | 317,041 | 148,160 | 177,704 | 124,969 | Upgrade
|
| Unlevered Free Cash Flow | 338,076 | 317,058 | 148,198 | 177,734 | 125,008 | Upgrade
|
| Change in Net Working Capital | -19,886 | -69,932 | 145,315 | 43,954 | 32,248 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.